FridayJun 23, 2023 3:15 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Secures Contract Renewal with K-FLEX de México

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process as well as providing its Fr8App platform for B2B cross-border shipping in the USMCA region. The company announced that it has been recognized for outstanding service by K-FLEX de México and has secured a renewal of its contract with K-FLEX. The contract is for continued utilization of the Fr8App platform to facilitate transportation of shipments from K-FLEX’s recently expanded Mexican plants and distribution centers across the United States. “Fr8App delivered cross-border capacity during a difficult time for us as we worked…

Continue Reading

ThursdayJun 22, 2023 3:50 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) to be Showcased at Upcoming Tesla Event

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, has announced that its Robot Roadshow will be landing in San Luis Obispo, California, at Tesla Takeover 2023. The announcement reads, “Tesla Takeover is July 29-30, 2023, at the Fields at Madonna Inn located at 100 Madonna Road in San Luis Obispo and is open from 10:00 a.m. to 4:00 p.m. Pacific Time. The third annual Tesla Takeover – the largest Tesla owners’ event in North America – brings together Tesla owners, EV enthusiasts and industry experts to celebrate the future. The keynote speaker…

Continue Reading

ThursdayJun 22, 2023 11:45 am

TinyGemsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) 755-201-EB Trial Demonstrates Clinically Important Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced safety and efficacy results from its phase 2 clinical trial. The purpose of the trial, called “755-201-EB,” was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (“EB”). According to the announcement, of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in…

Continue Reading

WednesdayJun 21, 2023 1:24 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Secures New Orders for K1 Retrofit, Call Boxes

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, has announced its receipt of a purchase order from San Francisco Bay Area Rapid Transit (“BART”) to expand its emergency communications system with three K1 Call Boxes. In addition, a university in the northeast is updating two of its antiquated devices using the Knightscope K1 Retrofit Kit. The announcement reads, “Knightscope’s modern emergency phones and call boxes are extremely cost-effective systems that use cellular and satellite communications with optional solar power. Knightscope’s leading-edge communications products and Autonomous Security Robot (‘ASR’) services provide reliable technologies…

Continue Reading

WednesdayJun 21, 2023 12:54 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Moratorium on New Financings, Sufficient Capital for at Least 12 Months

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced an investor financing moratorium for the balance of 2023 and that it has sufficient capital on hand for at least the next 12 months. In addition, the company confirmed that remaining investor option expires on June 30, 2023, and that its assets are unencumbered with the exception of $7.3 million outstanding debt. Mullen continues to trade at a steep discount to its current cash position of $135 million or $0.38 per share as of June 13, 2023. The company’s book value was $2.08 per share ss of its…

Continue Reading

TuesdayJun 20, 2023 2:11 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian patents, its 18th in its patent family No. 1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof, and No. 8 in its: Compositions Infused with Nicotine Compounds and Methods of Use Thereof. Lexaria was also granted two new U.S. patents under its patent family No. 21.  The first being for Pharmaceutical Compositions and Methods for Treating Hypertension, as well as the second being for Compositions and Methods…

Continue Reading

TuesdayJun 20, 2023 12:29 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Working on Broad Commercialization of AI-Powered PERSONA Vehicle Technology

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced the integration of AI-powered PERSONA vehicle technology into its overall commercial and consumer vehicle lineups. Originally developed for the Mullen FIVE, PERSONA is an advanced interactive AI camera/sensor and video monitoring system that utilizes facial recognition technology to unlock/lock vehicles and completely personalize the overall vehicle experience for the driver. “Right from the beginning, when we first introduced PERSONA at the 2021 LA Auto Show, the amount of positive feedback we’ve received has been far beyond anything we imagined; so, of course, we had to expand it for…

Continue Reading

TuesdayJun 20, 2023 10:30 am

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Announces Upcoming Robot Roadshow in West Texas

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, is releasing the next landing destination for its popular Robot Roadshow. The company announced that the engaging, in-person experience is slated to be at the Outlet Shoppes at El Paso on June 20–21, 2023; the roadshow will be open 10 a.m. to 2 p.m. each day. According to the announcement, the Outlet Shoppes at El Paso is the only outlet shopping center in the area. The center houses almost 100 name-brand stores as well as amenities such as a dancing water fountain, strollers,…

Continue Reading

FridayJun 16, 2023 2:25 pm

TinyGemsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC”) who have experienced disease progression after previous treatments. “REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC,” a recent article explains. “During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment. However, the findings also have revealed promising efficacy results. One…

Continue Reading

FridayJun 16, 2023 11:46 am

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the company’s proprietary DehydraTECH-CBD. DehydraTECH is a patented drug-delivery formulation and processing platform technology developed by Lexaria. The company noted that in addition to the three positive outcomes reported earlier — weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels — the study has indicated a reduction in blood glucose levels and improvements in kidney function. These results were gathered after the company undertook a further round of analysis to explore additional study…

Continue Reading

Contact us: (512) 354-7000